Analyst Naz Rahman of Maxim Group reiterated a Buy rating on Cingulate Inc, retaining the price target of $8.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Naz Rahman has given his Buy rating due to a combination of factors surrounding Cingulate Inc.’s recent developments and strategic partnerships. The company has submitted a New Drug Application (NDA) for its lead product, CTx-1301, aimed at treating ADHD, which could potentially receive FDA approval by the third quarter of 2026. This submission marks a significant milestone, indicating progress in their clinical development pipeline.
Additionally, Cingulate’s partnership with Indegene, a company with over 20 years of experience in the pharmaceutical commercialization space, enhances its commercial strategy. Indegene’s expertise in AI-driven analytics and comprehensive commercialization services provides Cingulate with a robust platform to optimize the launch and market penetration of CTx-1301. Despite current investor concerns about regulatory risks and market conditions, the potential best-in-class efficacy of CTx-1301 and the strategic collaboration with Indegene position Cingulate favorably for future growth and success.
According to TipRanks, Rahman is an analyst with an average return of -17.6% and a 29.13% success rate. Rahman covers the Healthcare sector, focusing on stocks such as Kazia Therapeutics, Aytu BioScience, and Silexion Therapeutics.